Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-FR | Version v3-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2022-05-09 | 2022-01-13 |
| Drug Identification Number | 02474719 | 02474719 |
| Brand name | PENTHROX | PENTHROX |
| Common or Proper name | Methoxyflurane Volatile liquid for inhalation | Methoxyflurane Volatile liquid for inhalation |
| Company Name | ENDO OPERATIONS LTD. | ENDO OPERATIONS LTD. |
| Ingredients | METHOXYFLURANE | METHOXYFLURANE |
| Strength(s) | 99.9% | 99.9% |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INHALATION INHALATION | INHALATION INHALATION |
| Packaging size | 3ml 10's | 3ml 10's |
| ATC code | N02BG | N02BG |
| ATC description | ||
| Reason for shortage | Other (Please describe in comments) | Delay in shipping of the drug. |
| Anticipated start date | 2022-01-12 | 2022-01-12 |
| Actual start date | 2022-01-12 | 2022-01-12 |
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | We wish to advise that MDI and Purdue Pharma (Canada) have terminated their commercial arrangement respecting the distribution of Penthrox® (methoxyflurane) in Canada. MDI is transitioning the distribution rights for Penthrox® to a new distributor, namely, Paladin Labs. Paladin Labs will require certain licenses and approvals to distribute Penthrox® in Canada. During the transition process, Penthrox® will not be available in the market for a period of time. Paladin Labs will provide further communication to keep you informed as the transition progresses and as stock becomes readily available. We apologize for any inconvenience and thank you for your on-going support of Penthrox®. | |
| Health Canada comments |